Dapagliflozin/metformin
Dapagliflozin/metformin, sold under the brand name Xigduo XR among others, is a fixed-dose combination anti-diabetic medication used as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes. It is a combination of dapagliflozin and metformin. Dapagliflozin/metformin was approved for use in the European Union in January 2014, and for use in the United States in February 2014. It is taken by mouth.
Q1779868
fixed-dose combination
Concept
Q575062
anti-diabetic medication
Concept
Q1100933
glycemic control
Concept
Q3025883
type 2 diabetes
Concept
Q409898
dapagliflozin
Concept
Q19484
metformin
Concept
Q85755685
Dapagliflozin/metformin
UNK
Q85755685
Dapagliflozin/metformin
UNK
2014-01-01T00:00:00Z^^http://www.w3.org/2001/XMLSchema#dateTime
January 2014
DATE
2014-02-01T00:00:00Z^^http://www.w3.org/2001/XMLSchema#dateTime
February 2014
DATE
+2^^http://www.w3.org/2001/XMLSchema#decimal
2
NUMBER
use